Literature DB >> 19886790

Erythropoietin and tumor angiogenesis.

Domenico Ribatti1.   

Abstract

Erythropoietin (Epo) may be considered as an endogenous stimulator of vessel growth during tumor progression through an autocrine and/or paracrine loop. The vascular effects of Epo would be relevant in tumor angiogenesis and the negative effect of Epo on tumor growth may be aggravated by its angiogenic activity. The mechanism of tumor growth in the context of Epo is not completely clarified, and it is still not clear whether there is a direct effect of Epo in tumor cells as opposed to exogenous effect on angiogenesis. It is also possible that the effect of Epo is multifactorial depending on the type of tumor and level of functionality of Epo receptor expression in tumor cells, as well other variables such as hypoxic stress, degree of anemia, chemotherapy, radiotherapy of surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19886790     DOI: 10.1089/scd.2009.0402

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  20 in total

1.  A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma.

Authors:  Dana A M Mustafa; Lennard J Dekker; Christoph Stingl; Andreas Kremer; Marcel Stoop; Peter A E Sillevis Smitt; Johan M Kros; Theo M Luider
Journal:  Mol Cell Proteomics       Date:  2012-01-25       Impact factor: 5.911

2.  Epo is involved in angiogenesis in human glioma.

Authors:  Beatrice Nico; Tiziana Annese; Diego Guidolin; Nicoletta Finato; Enrico Crivellato; Domenico Ribatti
Journal:  J Neurooncol       Date:  2010-07-09       Impact factor: 4.130

3.  Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.

Authors:  Zhihong Yang; Baocun Sun; Xiulan Zhao; Bing Shao; Jindan An; Qiang Gu; Yong Wang; Xueyi Dong; Yanhui Zhang; Zhiqiang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Dual Delivery of EPO and BMP2 from a Novel Modular Poly-ɛ-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps.

Authors:  Janki Jayesh Patel; Jane E Modes; Colleen L Flanagan; Paul H Krebsbach; Sean P Edwards; Scott J Hollister
Journal:  Tissue Eng Part C Methods       Date:  2015-07-22       Impact factor: 3.056

5.  Epigenetic silencing of erythropoietin in human cancers.

Authors:  Katrin Steinmann; Antje M Richter; Reinhard H Dammann
Journal:  Genes Cancer       Date:  2011-01

6.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

7.  Erythropoietin increases macrophage-mediated T cell suppression.

Authors:  Michelle A Wood; Naomi Goldman; Kelley DePierri; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2016-05-27       Impact factor: 4.868

8.  Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis.

Authors:  Yusuke Shiozawa; Samantha McGee; Michael J Pienta; Natalie McGregor; Younghun Jung; Kenji Yumoto; Jingcheng Wang; Janice E Berry; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2013-11       Impact factor: 4.429

9.  Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis.

Authors:  Jinsheng Yang; Zheng Xiao; Tao Li; Xuanmin Gu; Bo Fan
Journal:  Int J Oncol       Date:  2011-11-11       Impact factor: 5.650

Review 10.  Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration.

Authors:  Hal E Broxmeyer
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.